No annual revenue total was found in REVIUM Rx.'s SEC filings.
REVIUM Rx. (RVRC) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $842,000 in cash and investments and $128,000 in total debt.
Revenue
—
Net income
$-13.45M
Operating cash flow
—
Free cash flow
—
EPS
$-0.22
Dividend per share
None
Shares outstanding
61.32M
Net cash
$714,000
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RVRC (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1839140
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
|---|---|
| Net income | -$13.4M |
| Diluted EPS | -$0.22 |
| Total assets | $8.3M |
| Total liabilities | $1.4M |
| Stockholders' equity | $6.9M |
| Cash and investments | $1.7M |
| Total debt | $101,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 22, 2026 | Jun 16, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 1, 2026 | May 27, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Officer or director change
|
Apr 20, 2026 | Apr 14, 2026 |
| 10-K | Annual report | Mar 31, 2026 | Dec 31, 2025 |
Source: SEC EDGAR filings. This is company-reported data, not investment advice.